TY - JOUR
T1 - A Cancer Nanovaccine Based on an FeAl-Layered Double Hydroxide Framework for Reactive Oxygen Species-Augmented Metalloimmunotherapy
AU - Chang, Mengyu
AU - Wang, Man
AU - Liu, Bin
AU - Zhong, Wenbin
AU - Jana, Deblin
AU - Wang, Yifan
AU - Dong, Shiyan
AU - Antony, Abin
AU - Li, Chunxia
AU - Liu, Yuhui
AU - Zhao, Zhongqi
AU - Lin, Jun
AU - Jiang, Wen
AU - Zhao, Yanli
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/3/19
Y1 - 2024/3/19
N2 - The complexity and heterogeneity of individual tumors have hindered the efficacy of existing therapeutic cancer vaccines, sparking intensive interest in the development of more effective in situ vaccines. Herein, we introduce a cancer nanovaccine for reactive oxygen species-augmented metalloimmunotherapy in which FeAl-layered double hydroxide (LDH) is used as a delivery vehicle with dihydroartemisinin (DHA) as cargo. The LDH framework is acid-labile and can be degraded in the tumor microenvironment, releasing iron ions, aluminum ions, and DHA. The iron ions contribute to aggravated intratumoral oxidative stress injury by the synergistic Fenton reaction and DHA activation, causing apoptosis, ferroptosis, and immunogenic cell death in cancer cells. The subsequently released tumor-associated antigens with the aluminum adjuvant form a cancer nanovaccine to generate robust and long-term immune responses against cancer recurrence and metastasis. Moreover, Fe ion-enabled T1-weighted magnetic resonance imaging can facilitate real-time tumor therapy monitoring. This cancer-nanovaccine-mediated metalloimmunotherapy strategy has the potential for revolutionizing the precision immunotherapy landscape.
AB - The complexity and heterogeneity of individual tumors have hindered the efficacy of existing therapeutic cancer vaccines, sparking intensive interest in the development of more effective in situ vaccines. Herein, we introduce a cancer nanovaccine for reactive oxygen species-augmented metalloimmunotherapy in which FeAl-layered double hydroxide (LDH) is used as a delivery vehicle with dihydroartemisinin (DHA) as cargo. The LDH framework is acid-labile and can be degraded in the tumor microenvironment, releasing iron ions, aluminum ions, and DHA. The iron ions contribute to aggravated intratumoral oxidative stress injury by the synergistic Fenton reaction and DHA activation, causing apoptosis, ferroptosis, and immunogenic cell death in cancer cells. The subsequently released tumor-associated antigens with the aluminum adjuvant form a cancer nanovaccine to generate robust and long-term immune responses against cancer recurrence and metastasis. Moreover, Fe ion-enabled T1-weighted magnetic resonance imaging can facilitate real-time tumor therapy monitoring. This cancer-nanovaccine-mediated metalloimmunotherapy strategy has the potential for revolutionizing the precision immunotherapy landscape.
KW - augmented reactive oxygen species
KW - cancer nanovaccine
KW - dihydroartemisinin
KW - layered double hydroxides
KW - metalloimmunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85186692497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85186692497&partnerID=8YFLogxK
U2 - 10.1021/acsnano.3c11960
DO - 10.1021/acsnano.3c11960
M3 - Article
C2 - 38436248
AN - SCOPUS:85186692497
SN - 1936-0851
VL - 18
SP - 8143
EP - 8156
JO - ACS Nano
JF - ACS Nano
IS - 11
ER -